Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients

被引:34
|
作者
Bahl, Amit [1 ]
Johnson, Steven [1 ]
Chen, Nai-Wei [2 ]
机构
[1] Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48073 USA
[2] Beaumont Hlth Res Inst, Royal Oak, MI USA
关键词
Corticosteroids; Timing; COVID-19; Coronavirus; Treatment; Mortality;
D O I
10.1007/s11739-021-02655-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The optimal timing of initiating corticosteroid treatment in hospitalized patients is unknown. We aimed to assess the relationship between timing of initial corticosteroid treatment and in-hospital mortality in COVID-19 patients. In this observational study through medical record analysis, we quantified the mortality benefit of corticosteroids in two equally matched groups of hospitalized COVID-19 patients. We subsequently evaluated the timing of initiating corticosteroids and its effect on mortality in all patients receiving corticosteroids. Demographic, clinical, and laboratory variables were collected and employed for multivariable regression analyses. 1461 hospitalized patients with confirmed COVID-19 were analyzed. Of these, 760 were also matched into two equal groups based on having received corticosteroid therapy. Patients receiving corticosteroids had a lower risk of death than those who did not (HR 0.67, 95% CI 0.67-0.90; p = 0.01). Timing of corticosteroids was assessed for all 615 patients receiving corticosteroids during admission. Patients receiving first dose of corticosteroids > 72 h into hospitalization had a lower risk of death compared to patients with first dose at earlier time intervals (HR 0.56, 95% CI 0.38-0.82; p = 0.003). There was a mortality benefit in patients with > 7 days of symptom onset to initiation of corticosteroids (HR 0.56, 95% CI 0.33-0.95; p = 0.03). In patients receiving oxygen therapy, corticosteroids reduced risk of death in mechanically ventilated patients (HR 0.38, 95% CI 0.24-0.60; p < 0.001) but not in patients on high-flow or other oxygen therapy (HR 0.46, 95% CI 0.20-1.07; p = 0.07) and (HR 0.84, 95% CI 0.35-2.00; p = 0.69), respectively. Timing of corticosteroids initiation was related to in-hospital mortality for COVID-19 patients. Time from symptom onset > 7 days should trigger initiation of corticosteroids. In the absence of invasive mechanical ventilation, corticosteroids should be initiated if the patient remains hospitalized at 72 h. Hypoxia requiring supplemental oxygen therapy should not be a trigger for initiation of corticosteroids unless the timing is appropriate.
引用
收藏
页码:1593 / 1603
页数:11
相关论文
共 50 条
  • [1] Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients
    Amit Bahl
    Steven Johnson
    Nai-Wei Chen
    Internal and Emergency Medicine, 2021, 16 : 1593 - 1603
  • [2] Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
    Luís Coelho
    Fatima Falcão
    Pedro Póvoa
    Erica Viegas
    Antonio Pais Martins
    Eduarda Carmo
    Candida Fonseca
    Luis Campos
    Kamal Mansinho
    Inês Carmo
    Joana Soares
    Mariana Solano
    Dina Mendes
    Ana Cláudia Miranda
    Antonio Carvalho
    Ana Mirco
    Helena Farinha
    Isabel Aldir
    José Correia
    Scientific Reports, 13
  • [3] Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
    Coelho, Luis
    Falcao, Fatima
    Povoa, Pedro
    Viegas, Erica
    Martins, Antonio Pais
    Carmo, Eduarda
    Fonseca, Candida
    Campos, Luis
    Mansinho, Kamal
    Carmo, Ines
    Soares, Joana
    Solano, Mariana
    Mendes, Dina
    Miranda, Ana Claudia
    Carvalho, Antonio
    Mirco, Ana
    Farinha, Helena
    Aldir, Isabel
    Correia, Jose
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [4] Effect of Corticosteroids on Mortality in Hospitalized COVID-19 Patients Not Receiving Invasive Mechanical Ventilation
    Fusina, Federica
    Albani, Filippo
    Granato, Enza
    Meloni, Angelo
    Rozzini, Renzo
    Sabatini, Tony
    Stellini, Roberto
    Terragnoli, Paolo
    Rosano, Antonio
    Abu Hilal, Mohammed
    Natalini, Giuseppe
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1660 - 1667
  • [5] Predicting mortality in hospitalized COVID-19 patients
    Amedeo Tirandi
    Davide Ramoni
    Fabrizio Montecucco
    Luca Liberale
    Internal and Emergency Medicine, 2022, 17 : 1571 - 1574
  • [6] PREDICTORS OF MORTALITY IN HOSPITALIZED COVID-19 PATIENTS
    Khadzhieva, Maryam
    Gracheva, Alesya
    Yadgarov, Mikhail
    Pisarev, Mikhail
    Ershov, Anton
    Grebenchikov, Oleg
    Shabanov, Aslan
    Tutelyan, Alexey
    Kuzovlev, Artem
    ARCHIV EUROMEDICA, 2022, 12 (04):
  • [7] Predicting mortality in hospitalized COVID-19 patients
    Tirandi, Amedeo
    Ramoni, Davide
    Montecucco, Fabrizio
    Liberale, Luca
    INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (06) : 1571 - 1574
  • [8] Lupus anticoagulant and mortality in patients hospitalized for COVID-19
    Carmine Gazzaruso
    Giuseppe Mariani
    Carolina Ravetto
    Laura Malinverni
    Elena Tondelli
    Maria Cerrone
    Vittorio Sala
    Luigi Bevilacqua
    Teodoro Altavilla
    Adriana Coppola
    Pietro Gallotti
    Journal of Thrombosis and Thrombolysis, 2021, 52 : 85 - 91
  • [9] Lupus anticoagulant and mortality in patients hospitalized for COVID-19
    Gazzaruso, Carmine
    Mariani, Giuseppe
    Ravetto, Carolina
    Malinverni, Laura
    Tondelli, Elena
    Cerrone, Maria
    Sala, Vittorio
    Bevilacqua, Luigi
    Altavilla, Teodoro
    Coppola, Adriana
    Gallotti, Pietro
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (01) : 85 - 91
  • [10] Mortality in patients hospitalized with COVID-19 in northern Peru
    Leon-Jimenez, Franco
    Vives-Kufoy, Camila
    Failoc-Rojas, Virgilio E.
    Valladares-Garrido, Mario J.
    REVISTA MEDICA DE CHILE, 2021, 149 (10) : 1459 - 1466